FDA grants nivatrotamab Orphan Drug Designation and Rare Pediatric Disease Designation for the treatment of patients with neuroblastoma

Nivatrotamab, a humanised bispecific anti-GD2 antibody, is currently in Phase 1 clinical development in patients with relapsed/refractory neuroblastoma, as well as high grade osteosarcoma and other GD2(+) solid tumours, where patients have relapsed or refractory disease.

Source:

Biospace Inc.